Here are relevant reports on : oncology-drugs-market
-
Injectable Pharma Packaging Market by Type (Prefilled Syringes, Vials, Ampoules, Cartridges), Packaging Type (Primary, Secondary), Application (Chronic Disease Management, Vaccines, Biologics, Insulin, Oncology), and Region-Global Forecast to 2030
Injectable Pharma Packaging Market is projected to reach USD 98.8 billion by 2030 from USD 44.8 billion in 2025, at a CAGR of 17.5% during the forecast period. The key players in the injectable pharma packaging market include Schott AG (Germany), Gerresheimer AG (Germany), West Pharmaceutical Services (US), Stevanato Group (Italy), BD (Becton, Dickinson and Company) (US), SGD Pharma (France), Nipro Corporation (Japan), AptarGroup (US), Catalent, Inc. (US), and Datwyler Group (Switzerland).
- Published: April 2026
- Price: $ 4950
- TOC Available:
-
Rat Model Market by Model Type (Outbred, Inbred, Knockout), Technology (CRISPR, Micro Injection), Therapeutic Area (Neurology, Oncology), Service (Breeding, Cryopreservation), Care Products (Cages, Feed, Bedding) & End User -Global Forecast to 2021
The global rat model market is projected to grow at a CAGR of 8.7%. Continuous support in the form of investments and grants, and personalized medicine fueling the demand for personalized humanized rat models are some of the factors driving the growth of the rat model market. In addition to this, increase in R&D activities in pharmaceutical industries is further stimulating the market growth.
- Published: January 2017
- Price: $ 4950
- TOC Available:
-
Specialty PACS Market by Type (Radiology, Orthopedics, Oncology, Pathology, Endoscopy, Women's Health), Deployment Model (On premise, Cloud), Component (Software, Service), End User (Hospital, Clinic, Diagnostic Centers, Research) - Global Forecasts to 2024
The global specialty PACS market size is projected to reach USD 3.5 billion in 2024, at a CAGR of 6.0%. Some of the prominent players offering in this market includes IBM Corporation (Merge Healthcare Incorporated) (US), McKesson Corporation (US), Agfa Healthcare (Belgium), Carestream Health (a part of Onex Corporation) (Canada), Philips Healthcare (Netherlands), Sectra AB (Sweden), Siemens Healthineers (Germany), Novarad (US), INFINITT North America (US), Intelerad Medical Systems (Canada), Topcon Corporation (Japan), Sonomed Escalon (US), Canon USA, Inc. (US) (a subsidiary of Canon Inc.), Visbion (UK), and EyePACS, LLC (US).
- Published: September 2019
- Price: $ 4950
- TOC Available:
-
Bioanalytical Testing Services Market by Type, Application (Oncology, Neurology, Infectious Diseases, Gastroenterology, Cardiology), End User and Region (North America, Europe, APAC, Latin America, MEA) - Global Forecast to 2027
The global bioanalytical testing services market growth is primed to transition from $2.9 billion in 2022 to $6.0 billion by 2027, showcasing a strong CAGR of 15.6%. The major factors influencing the growth of the market include the well-established pharmaceutical industry, the strong presence of major service providers, the large number of ongoing clinical trial studies, high R&D expenditure, growth in the biosimilars and generics markets, and the rise in the outsourcing of preclinical, clinical, and laboratory testing services by pharmaceutical and biopharmaceutical companies in the region.
- Published: June 2022
- Price: $ 4950
- TOC Available:
-
Contrast Enhanced Ultrasound Market by Product (Equipment, Nanoparticle & Molecule-targeted Microbubbles, Software], Application (Diagnostic, Therapeutic, CVDs, Liver, Kidney, Oncology), End User (Hospital, Clinics, ASCs) & Region - Global Forecast to 2028
The global contrast enhanced ultrasound market, valued at US$1.4 billion in 2022, stood at US$1.6 billion in 2023 and is projected to advance at a resilient CAGR of 6.1% from 2023 to 2028, culminating in a forecasted valuation of US$2.1 billion by the end of the period. The rising use of contrast agents, increasing partnerships and collaborations, and the introduction of novel technologies are expected to drive the market during the forecast period.
- Published: August 2023
- Price: $ 4950
- TOC Available:
-
High Potency APIs Market / HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) & Region - Global Forecast to 2027
The global high potency APIs market growth is primed to transition from $24.5 billion in 2022 to $39.6 billion by 2027, showcasing a strong CAGR of 10.1%. This growth is driven by increasing demand for oncology drugs, advancements in HPAPI manufacturing technologies, and the rising focus on precision medicine.
- Published: May 2022
- Price: $ 4950
- TOC Available:
-
Radiation Dose Management Market by Offering (Product: Integrated, Standalone; Services), Modality (CT, Mammography, NM), Revenue Model (Pay-Per Procedure, Annual Purchase), Application (Oncology, Cardiology, Ortho), End User & Region - Global Forecast to 2028
The global radiation dose management market, valued at US$293 million in 2022, stood at US$343 million in 2023 and is projected to advance at a resilient CAGR of 13.8% from 2023 to 2028, culminating in a forecasted valuation of US$654 million by the end of the period. The growth of this market can be attributed to the increasing use of medical imaging modalities due to rising incidence of chronic diseases, increasing concerns over radiation dose exposure, growth in installation base of radiology equipment, and growing awareness about radiation dose management
- Published: January 2024
- Price: $ 4950
- TOC Available:
-
Photoacoustic Imaging Market by Product (Imaging System, Transducer, Software, Accessories), Technology (Microscopy, Tomography), Type (Preclinical, Clinical), Application (Oncology, Neuro), End User (Hospitals, Academia) & Region Global Forecast to 2029
The global Photoacoustic imaging market, valued at US$75M in 2023, is forecasted to grow at a 5.5% CAGR, reaching US$80M by 2024 and US$105M by 2029. The comprehensive research encompasses an exhaustive examination of industry trends, meticulous pricing analysis, patent scrutiny, insights derived from conferences and webinars, identification of key stakeholders, and a nuanced understanding of market purchasing dynamics.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Humanized Mouse and Rat Model Market by Type (Genetic Models, Cell-based Models, Rat Models), Application (Oncology, Immunology, Neuroscience, Toxicology, Infectious Diseases), End User (Pharma, Biotech), and Region - Global Forecast to 2030
The global humanized mouse and rat model market, valued at US$255.8M in 2024, is forecasted to grow at a 8.2% CAGR, reaching US$276.2M by 2025 and US$409.8M by 2030. The surge in the use of humanized models in drug discovery research, rising demand for personalized medicine, and increasing R&D activities in the pharmaceutical & biotechnology industry are contributing to market growth.
- Published: April 2025
- Price: $ 4950
- TOC Available:
-
Chemiluminescence Immunoassay Market by Product (Instruments, Consumables), Technology (CLEIA, ECLI, Microparticle CLIA), Sample Type (Blood, Saliva), Application (Oncology, Cardiology), End User (Hospital, Clinical Laboratory) - Global Forecast to 2031
The Chemiluminescence Immunoassay market, valued at US$10.89 billion in 2025, stood at US$11.58 billion in 2026 and is projected to advance at a resilient CAGR of 7.2% from 2026 to 2031, culminating in a forecasted valuation of US$16.39 billion by the end of the period. The chemiluminescence immunoassay (CLIA) market is experiencing rapid growth because increasing rates of chronic and infectious diseases create a need for precise diagnostic tests.
- Published: March 2026
- Price: $ 4950
- TOC Available:
Records 41 to 50 of 50
